representing three cancer types. One cell line per group expresses high levels of cell-surface GRP78, and the other expresses low levels (human hepatoma: Hep3B and HepG2; human prostate cancer: PC3 and 1-LN; and murine melanoma: B16F0 and B16F1). We investigated the effect of Escherichia coli Subtilase cytoxin catalytic subunit (SubA) on GRP78. We report that SubA specifically cleaves cell-surface GRP78 on HepG2, 1-LN, and B16F1 cells, without affecting intracellular GRP78. B16F0 cells (GRP78 low ) have a lower amounts of cleaved cell-surface GRP78. SubA has no effect on Hep3B and PC3 cells. The predicted 28 kDa GRP78 COOH-terminal fragment is released into the culture medium by SubA treatment, and COOH-terminal domain signal transduction is abrogated, whereas proproliferative signaling mediated through NH 2 -terminal domain ligation is unaffected. These experiments clarify cell-surface GRP78 topology and demonstrate that the COOH-terminal domain is necessary for pro-apoptotic signal transduction occuring upon COOH-terminal antibody ligation. SubA is a powerful tool to specifically probe the functions of cell-surface GRP78.
endoplasmic reticulum (ER) of all cell types, where it binds to nascent polypeptides and is responsible for sequestering these proteins until they can be properly folded and/or oligomerized. In a related role, GRP78 is important in the initiation of the Unfolded Protein Response (UPR). An increase of unfolded proteins in the ER leads to the dissociation of GRP78 from the UPR mediators PKR-like ER kinase (PERK), inositolrequiring enzyme 1(IRE1), and activating transcription factor 6 (ATF6), thereby allowing these transcription factors to become active. The UPR ultimately acts to promote either survival or apoptotic pathways in response to ER stress. Normal cellular function is therefore reestablished by reducing intermediate protein aggregates, increasing protein folding, regulating Ca 2+ , and repressing translation (1) . In addition to its role as a molecular chaperone in the ER, GRP78 is found in the cytoplasm, nucleus, and mitochondria, and it exists in secreted and plasma membraneassociated forms (2) (3) (4) (5) (6) . At the plasma membrane, GRP78 acts as a signaling receptor for activated 2 -macroglobulin ( 2 M*) (7, 8) . GRP78 at the cell surface is detected in multiple types of cancer cells both in vitro and in vivo and is usually not present on non-malignant cells (9, 10) . Furthermore, the expression of GRP78 on the cell surface is associated with tumor progression, metastasis, and a poor prognosis (11) . A recent report from our laboratory described the acceleration of murine melanoma growth by autoantibodies to GRP78 similar to those found in human cancer patients (12) . The selective expression of GRP78 on multiple types of tumors as compared to normal tissues makes it a particularly enticing anticancer therapeutic target.
Cell-surface GRP78 responds differently to ligation depending on whether the ligand recognizes the NH 2 -terminal domain (NTD) or the COOH-terminal domain (CTD) of GRP78, both of which are located on the extracellular side of the cell membrane. Activated forms of the plasma proteinase inhibitor, 2 M* bind to the NTD of GRP78 and stimulate survival and proliferation in a number of cancer cell types (13, 14) . The binding of 2 M* to 1-LN prostate cancer cells promotes their proliferation in both a MAPK-and PI3K-dependent manner (15) . Autoantibodies that recognize an epitope in the NTD of GRP78 often occur in prostate cancer (16) , ovarian cancer (17) , and melanoma (12) and are correlated with a poor prognosis. This epitope in the NTD of GRP78 is in the same ligand-binding region that is bound by 2 M*. In a manner antagonistic to the NTD signaling, exogenous CTD-reactive antibodies upregulate p53 and promote apoptosis in prostate cancer cells (18) .
The Subtilase cytotoxin (SubAB) represents the fourth and most recently discovered family of AB5 toxins. It is produced by certain virulent strains of Shiga toxigenic Escherichia coli (STEC) and was first isolated from a strain of STEC that caused an outbreak of hemolytic uremic syndrome (HUS) in South Australia. The SubAB holotoxin is composed of a 35 kDa catalytic "A" subunit (SubA) and five 13 kDa "B" subunits (SubB). The "A" subunit contains the catalytic triad Asp, His, and Ser. Mutation of any of these three resides results in a catalytically inactive enzyme. Studies demonstrate that the serine protease activity is necessary for its cytotoxic effects. SubB mediates binding to glycan receptors on the cell surface and is necessary to trigger internalization and subsequent trafficking of the holotoxin to the ER (19) . It is interesting to note that this process is clathrin-dependent and does not occur via lipid rafts (20) . Notably, SubB binds preferentially to a non-human glycan, 2-3 linked N-glycolylneuraminic acid (Neu5Gc) (21) . This glycan is not synthesized in humans; however, it is obtained through the ingestion of food derived from organisms that endogenously produce it.
The SubA serine proteinase displays extreme substrate specificity, and its only identified substrate is the ER chaperone, GRP78. SubA cleaves GRP78 between the amino acid residues Leu 416 -Leu
417
. This cleavage site is located within the hinge region between the ATPase and COOH-terminal protein binding domains, and cleavage at this site leads to the production of a 28 kDa COOH-terminal fragment (22) . Previous studies have shown that cleavage of ER GRP78 by SubAB leads to induction of the UPR through activation of PERK, IRE1, and ATF6 (23) (24) (25) . Additionally, treatment of cells with SubAB leads to apoptosis due to induction of the Bax/Bak-dependent apoptotic pathways (26) .
In this study, we report the novel observation that SubA specifically cleaves cellsurface GRP78. We used six different cells lines from three separate cancers (human hepatoma, human prostate cancer, and murine melanoma) for these studies. Two cell lines from each cancer type were chosen, with one cell line expressing high levels of cell-surface GRP78 and the other expressing low levels of cell-surface GRP78. We show that in cells that highly express cell-surface GRP78, SubA treatment abrogates the effects of CTD-reactive antibodies to GRP78, whereas in cells that express little or no cell-surface GRP78, both SubA and antibody treatment have virtually no effect. Additionally, cleavage of the CTD of GRP78 by SubA has no effect on signaling initiated through the NTD, indicating that SubA treatment is not only specific to GRP78, but does not affect signaling pathways other than those triggered by CTD binding. The fact that this phenomenon was seen in all cell lines studied suggests that SubA can be used to investigate the functions of cell-surface GRP78 in a wide variety of cell types, and the fact that SubA treatment has no effect on cells that do not express cell-surface GRP78, demonstrates the specificity of this enzyme. Moreover, this exquisite substrate specificity of SubA for GRP78 suggests that it may be of great utility in targeting cancer cells.
EXPERIMENTAL PROCEDURES Antibodies and Proteins
Anti-GRP78 N20 (Cat. No. SC-1050) and C20 (Cat. No. SC-1051) antibodies and the MTJ-1 antibody (Cat. No. SC-104898) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Non-immune goat IgG was purchased from Sigma (Sigma-Aldrich, St Louis, MO). 2 M isolated from human plasma was used to prepare the receptor recognized form ( 2 M-MeNH 2 ) 2 M*, as previously described (27). A recombinant murine cDNA expression construct encoding full-length rGRP78 with a 6-His tag in pET15b was the kind gift of Dr Sylvie Blond. This rGRP78 was expressed and purified as previously described (28) . SubAB, SubA A272 B, SubA, and SubA A272 were purified as previously described (19, 22) .
Cell Culture
HepG2, Hep3B, B16F0, B16F1, and PC3 cells were purchased from the American Type Culture Collection. 1LN cells were a kind gift from Dr. Phillip Walther (Duke University Medical Center, Durham, NC). HepG2 and Hep3B cells were grown in Minimum Essential Medium Eagle's (MEME) containing 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate, and 1X nonessential amino acids. B16F1 and B16F0 cells were grown in Dulbecco's Modified Essential Medium (DMEM) containing 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. PC3 and 1LN cells were grown in RPMI 1640 Medium containing 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. All cells were maintained in a humidified 37 °C incubator at 5% CO 2 
Cell Surface Biotinylation
Cells were biotinylated using the Pierce Cell Surface Protein Isolation Kit (Pierce, Rockford, IL) according to the manufacturer's instructions.
Western Blot Analysis
Cell culture supernatants from all cells that were treated with subtilase enzymes were collected and concentrated 10X in centrifugal filter units (Millipore, Billerica, MA). The cells were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton-X100) containing proteinase and phosphatase inhibitors (Halt Protease and Phosphatase Inhibitor Cocktail, Pierce, Rockford, IL). The protein concentrations of all samples were quantified using a commercially available BCA kit (Bio-Rad, Hercules, CA). Ten g of protein per sample was separated by SDS-PAGE and transferred to nitrocellulose. Membranes were probed with C20 antibody (0.2 mg/ml, diluted 1:500), followed by secondary anti-goat IgG antibody conjugated to an IR-700 nm label (Rockland, Gilbertsville, PA). The probed membranes were scanned on a Li-Cor Odyssey instrument (Li-Cor Biosciences, Lincoln, NE).
Microscopy
All cells were grown on chamber slides in complete medium overnight. 
Proliferation Assays
Cells in log-phase growth were seeded at 5×10 3 cells per well and allowed to grow for 24 h in 96-well plates. They were washed once with the appropriate serum-free medium, and were then left untreated or treated with 1 µg SubA or SubA A272 per 1×10 6 cells for 4 h. They were washed once with the appropriate serum-free media and the media was replaced with the appropriate complete medium or antibody preparation in serum-free medium supplemented with 1 µg SubA or SubA A272 per 1×10 6 cells. The cells were incubated overnight. The next morning, 0.5 µCi [ 3 H] thymidine was added to each well. Proliferation continued for 8 h until the media were removed and the cells were dissociated in 10X trypsin-EDTA and harvested using a 12-channel microharvester (Skatron Instruments, Molecular Devices, Downington, PA). The samples were counted in a scintillation counter. All of the conditions were performed in quadruplicate, and the experiments were repeated at least twice.
Total Akt and Phospho-Akt Assays
Cells in log-phase growth were seeded at 5×10 5 cells per well and allowed to grow for 24 h in 6-well plates. They were washed once with the appropriate serum-free medium, and were then left untreated or treated with 1 µg/ml SubA or SubA A272 per 1×10 6 cells for 8 h. The medium was replaced and cells were treated with 100 pM 2 M*, 10 µg/ml N20, 10 µg/ml C20, 10 µg/ml Goat IgG or left untreated for 15 min at 37 °C. Cells were then washed and lysed in RIPA buffer containing 6 M urea and proteinase and phosphatase inhibitors on ice for 15 min. Cell lysates were analyzed for total Akt and phosphoAkt by ELISA according to the manufacturer's instructions (R&D Systems, Minneapolis, MN). All conditions were performed in triplicate and were repeated at least twice.
For Ca 2+ -dependence assays, the experiments were performed as described above; however, prior to treatment with the stimuli, the cells were incubated with 10 M BAPTA-AM (Invitrogen, Carlsbad, CA) for 1 h.
Apoptosis Assay
Cells in log-phase growth were seeded at 2×10 4 cells per well and allowed to grow for 24 h in white-sided 96-well plates. They were washed once with the appropriate serum-free medium, and were then left untreated or treated with 1 µg SubA or SubA A272 per 1×10 6 cells for 8 h. The media was replaced with the appropriate complete medium or antibody preparation supplemented with 1 µg SubA or SubA A272 per 1×10 6 cells. After 16 h, cells were assayed using the Caspase-Glo 3/7 Assay System (Promega, Madison, WI) according to the manufacturer's instructions. The samples were counted on a luminometer and all conditions were performed in quadruplicate and were repeated at least twice.
Flow Cytometry
Cells were seeded at 1x10 6 per well in a 6 well plate and allowed to grow for 24 h. They were washed once with the appropriate complete medium, and treated with 1 g SubA or SubA A272 per 1×10
6 cells for 8 h in the appropriate complete medium. After 8 h, cells were scraped and resuspended at 1×10 6 /ml in HBSS with 0.5% BSA. Cells were stained with 5 g per 1×10 6 cells of anti-GRP78 C20, N20 (Santa Cruz Biotechnology, Santa Cruz, CA) or non-immune goat IgG for 1 h at 4 C. Cells were washed twice with PBS and FITC-labeled secondary goat IgG antibody was added at a final concentration of 1 g/10 6 cells for 30 min at 4 C. We used 7-amino actinomycin D (7-AAD, Becton-Dickinson, Franklin Lakes, NJ) according to the manufacturer's instructions for the exclusion of dead cells. Samples were analyzed on a Guava EasyCyte Plus (Millipore, Billerica, MA) and data analyzed with FlowJo 7.5 (Ashland, OR). Experiments were performed at least thrice.
Calcium Signaling Studies
Cells were seeded at 1×10 4 cells per dish in glass-bottomed 35 mm Petri dishes and were allowed to grow overnight. The next day, the cells were washed with complete medium and treated with 1 g SubA or SubA S272A per 1×10 6 cells for 8 h in the appropriate complete medium. After 8 h, FURA-2/AM (Invitrogen, Carlsbad, CA) was added to the cells at a final concentration of 4 M for 60 min at 37 C in the dark. Human FcR Block (Miltenyi, Auburn, CA) was added for the final 10 min at 4 C in the dark. Cells were washed twice with HBSS and relative [Ca 2+ ] i was subsequently measured using digital imaging microscopy as previously described (29) . After obtaining baseline measurements, 10 g of either anti-GRP78 N20 or C20 antibody or non-immune goat IgG was added and multiple measurements were taken every 5 sec over 10 min. [Ca 2+ ] i of these cells in response to antibody treatment was indicated by the ratio of emitted fluorescence of cytoplasmic FURA-2/AM caused by alternating 340 and 380 nm light excitations (340 nm/380 nm). We collected data from 5 to 10 cells per high-power microscope field, and experiments were repeated thrice. The data were analyzed with SimplePCI 6 (Hamamatsu Corporation, Serwickley, PA).
Statistical Analysis
All statistical analyses were performed with GraphPad Prism, version 5.0 (GraphPad Software, Inc., La Jolla, CA).
RESULTS

SubA cleaves rGRP78 with the same kinetics as SubAB
The holoenzyme SubAB cleaves both recombinant and endogenous GRP78 (22) . SubA is the catalytic subunit and should therefore cleave rGRP78 in a manner analogous to that of the holoenzyme. Additionally, the catalytically inactive Ser 272 Ala mutant of SubA should not cleave GRP78. To test this, rGRP78 was subjected to cleavage by either SubA or SubA A272 at 1 g/ml for up to 24 h. Untreated rGRP78 migrated at 75 kDa, and rGRP78 treated with SubAB and SubA showed the appearance of a 28 kDa and a 48 kDa band and a decrease in the 75 kDa band starting as early as 5 min (Figures 1A and B) . In contrast, the SubA A272 did not cleave rGRP78, even at 24 h ( Figure 1C ).
SubA cleaves cell-surface GRP78 specifically
SubA by itself cannot enter cells because it is the B subunit that binds to its cognate glycan receptors on cells and triggers the internalization and subsequent intracellular trafficking of the holoenzyme (21) . However, because SubA remains catalytically active without the B subunit, it should cleave cell-surface GRP78. We tested this hypothesis by treating six different cell lines with SubAB, SubA A272 B, SubA, or SubA A272 . For the following experiments, we utilized six different cells lines representing three different cancers, and for each cancer type, one cell line expressed high levels of cell-surface GRP78 and the other cell line expressed low or no cell-surface GRP78 (see flow cytometry section and unpublished observations). The HepG2 and Hep3B cell lines are human hepatoma cell lines and express high and low levels of cell-surface GRP78, respectively. The 1-LN and PC3 cell lines are human prostate cancer cell lines and express high and almost undetectable levels of cell-surface GRP78, respectively. The highly metastatic 1-LN cell line is derived from the less metastatic PC3 cell line. B16F0 and B16F1 cells are murine melanoma cell lines and express high and low levels of cell-surface GRP78, respectively. The B16F1 cell line is derived from the B16F0 cell line. The cells were grown to confluency and then treated with 1 g enzyme per 1×10
6 cells overnight at 37 C. The concentrated cell culture supernatants were analyzed by Western blot for full-length GRP78 and fragments thereof. We show that the treatment of HepG2, 1-LN, B16F1, and to a much lesser extent, B16F0 cells with SubAB and SubA, but not SubA A272 B or SubA A272 , leads to the accumulation of a 28 kDa species in the cell culture supernatant of these cells. This protein is identified as a fragment of GRP78 by immunoblotting with anti-GRP78 C20 antibody (Figure 2A ). PC3 and Hep3B cells express very low amounts of cell surface GRP78 and the 28 kDa species was not detected in the cell culture supernatant. Although SubAB also cleaved cellsurface GRP78, the cells looked very unhealthy. All of the cell lines treated with SubAB were rounded in appearance and were becoming less adherent (data not shown), and this was most likely due to the cleavage of ER GRP78, which ultimately leads to cell death (22) . However, the SubA-treated cells appeared similar to the untreated control cells (data not shown), indicating that treatment with this enzyme alone is not harmful to cells.
To ensure that the cleaved fragment of GRP78 was released from cell-surface GRP78, we biotinylated the surface of these cells using a cellimpermeable, cleavable biotinylation reagent that labels exposed primary amines on the cell surface (Pierce, Rockford, IL). After biotinylation, the cells were treated in the same manner as above. Again, cleavage of cells with SubA led to the accumulation of a 28 kDa species in the cell culture supernatant that interacted with both an anti-biotin antibody ( Figure 2B ) and with the C20 antibody ( Figure 2C ) for HepG2, 1-LN, B16F1, and to a much lesser extent, B16F0 cells. PC3 and Hep3B cells had no biotin-reactive or C20-reactive species in the cell culture supernatant because they have very little cell-surface GRP78. This confirms that the GRP78 cleavage product was a cleavage product of the GRP78 CTD at the cell surface and was not released from internal stores.
To investigate the kinetics of cell-surface GRP78 cleavage, we performed a time course experiment of GRP78 cleavage on the surface of all six cell lines. The cells were grown to confluency and then left untreated or treated with 1 g SubA or SubA A272 per 1×10 6 cells for 0, 1, 2, 4, 12, and 24 h at 37 C. Concentrated cell culture supernatants were analyzed for the 28 kDa fragment of GRP78. We show that SubA cleavage of cell-surface GRP78 is detectable as early as 1 h and continues for up to 24 h for cells that have detectable levels of cell-surface GRP78. SubA A272 does not cleave cell-surface GRP78 at any of the time points ( Figure 2D ). Cells were also harvested and analyzed for intracellular GRP78 expression by immunoblotting with the C20 antibody. This was performed to ensure that enzymatic cleavage of cell-surface GRP78 did not affect intracellular GRP78 expression levels. None of the treatment groups in any of the cell lines showed an increase in intracellular GRP78 expression over time compared to the untreated control ( Figure 2E ), indicating that cleavage of cell-surface GRP78 does not affect intracellular GRP78 levels.
Cleavage of cell-surface GRP78 reduces CTD antibody binding
To visually demonstrate that cell-surface GRP78 is cleaved, we analyzed untreated, SubAtreated or SubA A272 -treated cells by fluorescence microscopy. The cells were seeded on chamber slides and were treated with 1 g SubA or SubA A272 per 1×10 6 cells or left untreated. Unpermeabilized, fixed cells were then stained with the anti-GRP78 C20 antibody and were visualized by fluorescence microscopy. We demonstrate that the cleavage by SubA of cellsurface GRP78 on HepG2, 1-LN, B16F1, and to a much lesser extent, B16F0 cells, completely abolishes the fluorescent signal when stained with anti-GRP78 C20 (Figure 3) . The SubA A272 -treated cells were stained similarly to the untreated control cells. PC3 and Hep3B cells did not have a detectable GRP78 immunofluorescence signal when stained with anti-GRP78 C20 antibody because these cells do not express cell-surface GRP78. In contrast, anti-GRP78 N20 staining was unaffected by cell-surface GRP78 cleavage for all cell lines (Supplementary Figure 1) .
Cell-surface GRP78 cleavage is detectable by flow cytometry
Cell-surface GRP78 is easily detectable by flow cytometry using both NTD-and CTDreactive antibodies (12) . Therefore, cleavage of cell-surface GRP78 by SubA should at least diminish the signal obtained by staining with C20 antibody, if not fully abolish it. In contrast, the signal obtained by staining with the N20 antibody should not be affected, unless cleavage of the CTD induces a conformational change that affects NTD antibody binding.
To test this hypothesis, we stained all six cell lines treated with the various subtilase enzymes with N20, C20, or non-immune goat IgG for analysis by flow cytometry. We show that treatment of cells with SubA, but not SubA A272 , reduces the GRP78 signal when stained with the C20 antibody for cell lines that express cellsurface GRP78 (Figure 4 and Table 1 ); however, the signal is unchanged when stained with N20 antibody (Supplementary Table 1 ). This indicates that cleavage of the CTD of GRP78 is detectable, through loss of signal, by flow cytometry, and that this cleavage does not induce a conformational change in the NTD of the protein.
To determine whether enzyme treatment leads to increased cell death, we also stained the cells with 7-AAD, which does not pass through intact cell membranes. Our analyses indicate that treatment with 1 g SubA or SubA A272 per 1×10 6 cells for 8 h does not significantly affect cell viability (Table 2 and Supplementary Table 2) .
Cell-surface GRP78 cleavage abrogates CTD antibody-induced proliferation inhibition
We have shown in DU145 and 1-LN prostate cancer cell lines that anti-CTD antibodies to GRP78 inhibit proliferation as measured by [ 3 H] thymidine uptake (18) . In this study, we cleaved cell-surface GRP78 with SubA and determined whether cell proliferation was affected when treated with the C20 or N20 antibody. Untreated cells and SubA A272 -treated cells demonstrated a dose-dependent inhibition of proliferation when treated with 0.1, 1.0, and 10.0 g/ml of C20 (Supplementary Table 3 ). However, the SubAtreated cells did not show any inhibition of proliferation and this effect was significant compared to both the untreated and SubA A272 -treated cells, and the untreated and SubA A272 -treated cells were not significantly different from each other ( Figure 5 and Table 3 ). Treatment with N20 antibody after SubA cleavage increased proliferation in a manner similar to that of the untreated and SubA A272 -treated cells. The goat IgG control did not affect proliferation in any of the treatment groups. Overall, the results of these experiments demonstrate that proliferation induced by the N20 antibody is not affected by SubA cleavage of the GRP78 CTD. However, SubA cleavage does abrogate the inhibition of proliferation caused by the C20 antibody in the cell lines that express cell-surface GRP78.
We have previously shown that phosphorylation of Akt is a necessary signaling step in the proliferation pathway that is activated by ligation of the NTD of GRP78 (15) . For this study, where we are specifically investigating CTD signaling and the effects of SubA on these events, Akt phosphorylation is not directly relevant because Akt is phosphorylated in response to ligation of the NTD of GRP78. However, to ensure that CTD cleavage of cellsurface GRP78 does not affect Akt phosphorylation triggered by NTD ligation, we analyzed untreated, SubA-treated and SubA A272 -treated cells for both total Akt and phospho-Akt levels. Cells were treated with 1 g enzyme per 1×10
6 cells for 8 h, followed by stimulation with 100 pM 2 M*, 1 µM staurosporine (STS), 10 µg/ml N20, 10 µg/ml C20, 10 µg/ml goat IgG or left untreated for 15 min at 37 °C. Cells lysates were analyzed by total and phospho-Akt ELISA and show that in all treatment groups, Akt is phosphorylated to a similar degree when stimulated with 2 M* or N20, while stimulation with C20 or goat IgG does not lead to increases in Akt phosphorylation, for cell lines that express cell-surface GRP78 ( Figure 6 and Table 4 ). These results are consistent with previous results from our laboratory (30) and indicate that cleavage of the GRP78 CTD does not affect the NTD, and that the signaling components associated with the NTD remain intact.
SubA cleavage of cell-surface GRP78 abrogates caspase 3/7 activation
In addition to testing for inhibition of proliferation, we directly tested the ability of CTD antibodies to cause apoptosis as measured by activation of the effector caspases 3/7. For the HepG2, 1-LN, B16F1, and to a lesser extent, B16F0 cells, the untreated and SubA A272 -treated cells showed caspase 3/7 activation when treated with 0.1, 1.0, or 10.0 g/ml of C20 antibody (Supplementary Table 4 ). However at the highest concentration of C20, the SubA-treated cells from these cell lines showed significantly less caspase 3/7 activation compared to the other two treatment groups ( Figure 7 and Table 5 ). This suggests that the CTD of GRP78 is indeed responsible for transducing the apoptotic signal initiated by ligation with the CTD-reactive antibody, C20. Treatment with N20 produced similar results for all three treatment groups. For the PC3 and Hep3B cell lines, both enzyme and antibody treatment had no effect on caspase 3/7 activation. The positive control, STS, activated caspase 3/7 to a similar degree in all treatment groups.
SubA cleavage of cell-surface GRP78 abolishes the Ca
2+ signal induced by the CTD antibody Previous work in our laboratory has shown that binding of 2 M*, NTD antibodies and CTD antibodies causes the release of Ca 2+ from intracellular stores (31) . Here, we show that cleavage by SubA abrogates the Ca 2+ signaling induced by the CTD antibody C20 as compared to both the untreated and SubA A272 -treated for HepG2 and 1-LN cells (Figure 8 and Table 6 ). The untreated and SubA A272 -treated cells were not significantly different from each other. Similar to both the proliferation and apoptosis data, the signal induced by treatment with N20 is not affected by SubA treatment and is proportional to that of the untreated and SubA A272 -treated cells (Supplementary Table 5 ). Again, this suggests that the cleavage of the CTD of GRP78 does not affect functions of the NTD of GRP78. For Hep3B cells, there was a very slight increase in Ca 2+ signal observed with both the N20 and C20 antibodies ( Figure 8 , Table 6 and Supplementary Table 5) ; however, this effect was not significant and was most likely due to the fact that Hep3B cells express a very low copy number of cell-surface GRP78. For the PC3 cells, there was no Ca 2+ signal with either the N20 or C20 antibody and this is because PC3 cells do not express cellsurface GRP78 (Figure 8 , Table 6 and  Supplementary Table 5) . Notably, we observed that treatment with N20 or C20 induced no Ca 2+ signal in both B16F0 and B16F1 cells (Figure 8 , Table 6 and Supplementary Table 5) ; however, both cell lines induce Akt phosphorylation when stimulated with the N20 antibody and 2 M*, suggesting that in these cell lines, Akt phosphorylation is Ca 2+ -independent. To test this hypothesis, we repeated the Akt phosphorylation studies using BAPTA-AM, a cell-permeable Ca 2+ chelator. We treated the cells as described previously, except that we incubated the cells with 10 M BAPTA-AM for 1 h prior to stimulation with the antibodies or 2 M*. We show that even in the absence of Ca 2+ , Akt is phosphorylated in response to N20 and 2 M* stimulation ( Figure 9 and Table 7 ). These results indicate that in B16F0 and B16F1 cells, Akt phosphorylation in response to NTD ligation by 2 M* and the N20 antibody is Ca 2+ -independent.
DISCUSSION
In these studies, we unequivocally show that cell-surface GRP78 is specifically cleaved by the catalytic subunit of the Subtilase cytotoxin, SubAB, the only member of a new family of AB 5 toxins. We show that the cleavage product is detectable in the cell culture supernatants of SubA-and SubAB-treated, but not SubA A272 B-, or SubA A272 -treated cells, and that cell-surface GRP78 cleavage does not affect intracellular GRP78 expression levels. We also show that the loss of this portion of GRP78 results in a decrease of CTD antibody staining as detected by fluorescence microscopy and flow cytometry. Cleavage of the COOH-terminal 28 kDa of GRP78 abrogates apoptosis caused by ligation of CTD antibodies to GRP78. Finally, we show that cleavage of GRP78 by SubA results in a decrease in the Ca 2+ signaling induced by CTD antibody binding to GRP78. Cleavage of cell-surface GRP78 by SubA has broad implications, not only for the study of GRP78, but the study of its role on the cell surface in cancer and infectious disease as a whole.
It is interesting to note that SubA is capable of cleaving cell-surface GRP78 on cells to a greater extent than the holotoxin, SubAB. The likely explanation is that if the B subunit is present, it will direct rapid binding to its cognate receptors on the cell surface and trigger uptake of the holotoxin. Thus, the A subunit is prevented from interacting significantly with cell-surface GRP78. Also, any holotoxin that remains on the cell surface bound to its glycan receptor will not be free to interact with GRP78. This may also explain the relatively high concentrations of SubA needed to achieve cell-surface GRP78 cleavage. Because there is no targeting subunit, a higher concentration of enzyme is needed to obtain the localized concentration of enzyme necessary for cleavage.
The presence of GRP78 in many cellular compartments (e.g., the ER, cytoplasm, nucleus, mitochondria, secretome, and cell surface) makes this protein difficult to study within any single compartment. Until now, the available methods of reducing GRP78 expression, such as RNAi knockdown and heterozygous mouse generation reduced global GRP78 expression without consideration for the cellular compartment of interest. In fact, GRP78 knockout mice are embryonically lethal (32) , and although conditional/temporal knockouts have been developed to overcome this problem (33), they do not address individual cellular compartments. RNAi knockdown of GRP78 also reduces the entire pool of GRP78 in a cell, although 100% knockdown is never attained. The specificity of SubA for cell-surface GRP78, as well as its inability to be internalized, provides a very elegant tool for studying cell-surface GRP78 without interference from intracellular processes dependent upon GRP78. Cleavage of cell-surface GRP78 by SubA allows us to study the receptor functions of GRP78 without the non-specific effects caused by knockdown or cleavage of ER GRP78.
Previous studies using transmembrane prediction programs have suggested that GRP78 has four potential transmembrane domains at the cell surface: I (a.a. 1-17), II (a.a. 29-45), III (a.a. 222-242), and IV (a.a. 414-431) (34) . However, the studies performed here demonstrate that at least residues 416-417 are exposed on the cell surface, as this is the sole SubA cleavage site and we observe cell-surface cleavage. Other reports propose that GRP78 is tethered to the cell surface via the DNA J like protein, MTJ-1 (35) . However, we have observed that MTJ-1 is not detectable on HepG2, Hep3B, 1-LN, PC3, B16F0, or B16F1 cell membranes (unpublished data). It is known that cell-surface GRP78 has a number of binding partners, including the teratocarcinoma-derived growth factor I (Cripto), the LDL receptor-related protein-1 (LRP1), the voltage-dependent anion channel (VDAC), and the major histocompatibility complex class I (MHC-I), depending on the cell type (36) . Therefore, it is possible that GRP78 associates with one of the above proteins or a new, unidentified binding partner in these cells. It may also associate with another member of the DNA J protein family; however, further investigation is warranted to determine the mechanism by which GRP78 is displayed on the surface of these cells. In fact, further investigation may show that GRP78 has different binding partners depending on the cell line and type of cancer that the cell line is derived from. Overall, although the predicted transmembrane domains I through III, and part of IV, may indeed be actual transmembrane domains, at least the first three residues of predicted transmembrane domain IV are exposed to the extracellular space.
We also show that cleavage of the CTD of cell-surface GRP78 results in an abrogation of signaling initiated by CTD antibody ligation of GRP78; however, signaling initiated by ligation of anti-NTD GRP78 antibodies was unaffected for the cell lines that expressed cell-surface GRP78. The anti-GRP78 antibodies or enzyme treatment did not affect the cell lines with little or no cellsurface GRP78 expression. Anti-CTD antibodies to GRP78 induce apoptosis via a p53-dependent mechanism (18) , while also decreasing expression of the anti-apoptotic protein Bcl-2 and increasing the expression of the pro-apoptotic proteins BAD, BAX, and BAK (30) . The levels of the cleaved caspases 3, 7, 8, and 9 were also elevated when cell-surface GRP78 was ligated with a CTD antibody (30) . We have also shown that NTD agonists promote cell survival and proliferation through activation of PI3K and Akt (30) .
We have previously studied the Ca 2+ release induced by anti-GRP78 antibodies isolated from the sera of prostate cancer patients on the highly metastatic prostate cancer cell line, 1-LN (31). Here, we used the N20 and C20 antibodies to induce Ca 2+ signaling in several cell lines. Again, for the cell lines that express cell-surface GRP78, both the N20 and C20 antibodies induce the release of Ca 2+ . However, the C20-induced Ca release is abrogated by SubA cleavage of the CTD of GRP78, while Ca 2+ release by the NTD-reactive N20 antibody is completely unaffected in these SubA-treated cells. This suggests that the COOHterminus of GRP78 does not interact with the NH 2 -terminus of GRP78 and is not necessary for signaling through the NH 2 -terminus. In effect, the two termini act as separate signaling compartments. For the cell lines that do not express cell-surface GRP78, enzyme treatment or antibody stimulation had no effect, meaning that there was no release of Ca 2+ . It is interesting to note that the B16F0 and B16F1 cell lines did not release Ca 2+ in response to antibody treatment. However, these cells do proliferate in response to treatment with the anti-GRP78 N20 antibody in an Akt-dependent manner, which is often a Ca 2+ -dependent process. To determine whether these cell lines phosphorylate Akt independent of Ca 2+ , we repeated the Akt assays in the presence of the cell-permeable chelator, BAPTA-AM. Again, we observed that Akt was phosphorylated in the absence of Ca 2+ , indicating that at least in these two cell lines, Akt phosphorylation is Ca 2+ -independent. This phenomenon has been observed in several other cell types, including macrophages (37), endothelial cells (38) , and smooth muscle cells (39) , where Akt activation by a variety of stimuli was achieved despite the chelation of Ca 2+ . Although the results with the B16F0 and B16F1 cell lines regarding Ca 2+ -dependence/ independence are primarily interesting, these finding have no direct bearing on our studies, because we are specifically investigating GRP78 CTD-dependent signaling. This proposed selective ligand determination of differential GRP78 signaling is not completely without precedent. Several lines of evidence from the 7-transmembrane domain and adrenergic receptor fields indicate that different adrenergic drugs can exhibit "biased agonism" when interacting with a single receptor type. The immediate branch-point in this system is selectivity for signaling via G-proteins or β-arrestins, with significantly different biological sequelae. This model has been explored both in vitro and in vivo using the β 2 -adrenergic receptors and angiotensin type 1 receptors as models (40) (41) (42) . Furthermore, regional bias in signaling has been demonstrated using the protease-activated receptors (PAR) as models, in which distinct patterns of PAR coupling to effector molecules depends on differential regional interactions with proteinases. This regional selectivity also leads to considerably different biological outcomes (43) .
The proliferation and apoptosis data presented here indicate that the CTD is indeed the region of GRP78 that is important for initiating apoptosis. This unequivocally confirms previous studies in our laboratory that indicate that the CTD of GRP78 is the site that transduces the apoptotic signal. The abrogation of signaling when HepG2, 1-LN, B16F1, and to a lesser extent, B16F0 cells, are treated with SubA suggests that the cleavage of the CTD of GRP78 would be protective against apoptosis caused by potential circulating CTDreactive antibodies.
GRP78 has been identified as a receptor for Dengue virus on HepG2 cells. It has been shown that NTD antibodies inhibit Dengue virus entry, while CTD antibodies enhance Dengue virus entry (44) . This suggests that cleavage of cell-surface GRP78 by SubA, or otherwise interfering with CTD availability may be a unique strategy for combating this disease.
In summary, the studies presented here demonstrate that cell-surface GRP78 is specifically cleaved by the catalytic subunit of the Escherichia coli Subtilase cytotoxin, and that this cleavage occurs in a variety of cell types that express cell-surface GRP78. Cells that do not express GRP78 are unaffected by SubA treatment.
The findings presented here demonstrate that SubA specifically cleaves cell-surface GRP78 and specifically abrogates GRP78 CTD-signaling. This provides us with a unique tool to study the receptor function of GRP78 on a variety of cell types without disturbing the intracellular compartments where GRP78 performs functions necessary for cell survival. 
